Adeela Mushtaq
Overview
Explore the profile of Adeela Mushtaq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majeed A, Larriva M, Iftikhar A, Mushtaq A, Campbell P, Nadeem Malik M, et al.
Infect Dis Clin Pract (Baltim Md)
. 2021 Jan;
28(1):10-15.
PMID: 33424210
Introduction: The aim of our study is to evaluate risk factors associated with the development of infection (CDI) in hematopoietic stem cell transplant (HSCT) patients, determine its incidence and report...
2.
Iftikhar A, Hassan H, Iftikhar N, Mushtaq A, Sohail A, Rosko N, et al.
Antibodies (Basel)
. 2019 Sep;
8(2).
PMID: 31544840
Background: Immunotherapy for multiple myeloma (MM) has been the focus in recent years due to its myeloma-specific immune responses. We reviewed the literature on non-Food and Drug Administration (FDA) approved...
3.
Mushtaq A, Iftikhar A, Hassan H, Lakhani M, Sagar F, Kamal A, et al.
Clin Lymphoma Myeloma Leuk
. 2019 May;
19(7):447-461.
PMID: 31060991
Introduction: Pomalidomide (Pom) has demonstrated synergistic antiproliferative activity in combination regimens as a result of its distinct anticancer, antiangiogenic, and immunomodulatory effects. This review aimed to compare outcome measures of...
4.
Fraz M, Warraich F, Warraich S, Tariq M, Warraich Z, Khan A, et al.
Crit Rev Oncol Hematol
. 2019 Apr;
137:18-26.
PMID: 31014512
Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous...
5.
Majeed A, Beatty N, Iftikhar A, Mushtaq A, Fisher J, Gaynor P, et al.
Transpl Infect Dis
. 2018 Apr;
20(4):e12904.
PMID: 29668074
Background: Nocardiosis is a life-threatening opportunistic infection. Solid organ transplant (SOT) recipients are at higher risk (incidence 0.04%-3.5%) of developing nocardiosis. Rate of nocardiosis in the Southwestern US may be...
6.
Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, McBride A, et al.
Crit Rev Oncol Hematol
. 2018 Apr;
125:1-11.
PMID: 29650268
Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids. Despite its notable efficacy, bortezomib has side effects like peripheral...
7.
Siyahian A, Malik S, Mushtaq A, Howe C, Majeed A, Zangeneh T, et al.
Biol Blood Marrow Transplant
. 2018 Mar;
24(7):1483-1489.
PMID: 29545185
Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) are at a very high risk of hepatitis B virus reactivation (HBVr). Lamivudine is commonly used as prophylaxis against HBVr in high-risk...
8.
Sohail A, Mushtaq A, Iftikhar A, Warraich Z, Kurtin S, Tenneti P, et al.
Immunotherapy
. 2018 Feb;
10(4):265-282.
PMID: 29421983
We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal...